Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clini…
Biotechnology
FR, Illkirch-Graffenstaden [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 69.48 | -7.28 | -23.85 | |
| Graham Fair Price | 42.60 | 0.47 | 0.33 | |
| PEG | -66.06 | -0.05 | 0.16 | |
| Price/Book | -14.01 | 8.82 | 10.26 | |
| Price/Cash Flow | 57.81 | -7.40 | -17.53 | |
| Prices/Earnings | 57.00 | -5.36 | -12.46 | |
| Price/Sales | 4717.18 | 4919.71 | 102.13 | |
| Price/FCF | 57.81 | -7.40 | -17.53 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -7087.81 | -249.34 | -3.47 | |
| Operating Margin | -13429.92 | -633.11 | -4.68 | |
| ROA | -100.00 | -0.14 | -0.07 | |
| ROE | -0.21 | -0.41 | -100.00 | |
| ROIC | -0.23 | -0.72 | -209.59 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.92 | 7.73 | -88.07 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.58 | -1.42 | 142.14 | |
| EPS QOQ | 0.80 | -1.02 | 26.67 | |
| FCF QOQ | 0.52 | -1.04 | 99.10 | |
| Revenue QOQ | 0.36 | -0.98 | 175.24 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 44.64 | 4696.07 | 10419.55 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.51 | 0.07 | -85.30 | |
| Quick Ratio | 1.64 | 1.71 | 4.15 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.15 | 0.16 | 0.83 | |
| Cash | 0.15 | 0.16 | 0.83 | |
| Capex | < 0.005 | -0.01 | -109.63 | |
| Free Cash Flow | -0.09 | -0.19 | -105.50 | |
| Revenue | 0.02 | < 0.005 | -98.20 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Weak